The Mazdutide Sourcing Audit: A Four-Point Checklist, and Nobody Passes

Every sourcing question can be reduced to a checklist and scored. That is the approach applied here to a specific question a lot of people are typing into search bars in 2026: where in America can you safely buy mazdutide, the dual GLP-1/glucagon drug that beat semaglutide head to head in trial data. The checklist has four line items. The scoring below is blunt. The short version, stated first so nobody has to read to the end for it: every channel selling mazdutide to Americans fails the checklist, because the drug itself fails a precondition none of the sellers mention. It has no US approval. What follows is the audit, the scorecard, and the one part of the map that actually scores well, which turns out not to be mazdutide at all.

First, the drug, stated without embellishment

Mazdutide is a real, data-backed molecule, not a forum rumor. It is an oxyntomodulin analog developed by Innovent Biologics with Eli Lilly, and it is the first approved agonist to hit both the GLP-1 and glucagon receptors at once [1][2]. The trial record is not thin:

• GLORY-1 (New England Journal of Medicine): Chinese adults with obesity or overweight lost roughly 11% of body weight on the 4 mg dose and about 14% on 6 mg, over 48 weeks, against placebo [1].
• GLORY-2: the 9 mg dose produced about 18.6% mean loss over 60 weeks, with completers approaching 20% [5].
• DREAMS-3: a head-to-head against semaglutide 1 mg in type 2 diabetes, mazdutide hit a combined target of blood-sugar control plus at least 10% weight loss in 48.0% of patients versus 21.0% on semaglutide [6][7].

Those numbers are why the drug generates real interest and why the gray market around it is worth taking seriously as a hazard, not dismissing as a curiosity. A dangerous product with unimpressive data is easy to walk away from. A dangerous product with data this good is the one people talk themselves into.

The precondition that sinks every score before scoring starts

Mazdutide is approved in China. It is not approved in the United States. China’s National Medical Products Administration cleared it for chronic weight management on June 27, 2025 under the brand name Xinermei, and added a type 2 diabetes indication in September 2025 [3][4]. In the US it remains investigational, tracked under Lilly’s code LY3305677, with no new drug application on file and no FDA clearance [2][8].

That fact does not knock a point off the scorecard. It disqualifies every entrant before the scoring starts, because “safe US purchase” requires a US-approved product to purchase, and there is not one. Every seller marketing mazdutide to an American customer is, by definition, offering something that is not an approved, accountable medicine. Keep that in mind through the scoring below.

The rubric

Four criteria, applied evenly to every channel:

1. Provenance. Is there a verifiable manufacturer and a supply chain that traces back to it?
2. Pharmacy accountability. Is a licensed pharmacy dispensing the product, with liability if it is wrong?
3. Batch-linked verification. Is there independent lab testing tied to the specific unit received, not a recycled document?
4. Clinical supervision. Did a clinician evaluate the buyer and manage the dose escalation, which matters here because mazdutide titrates upward over weeks and carries GI effects (nausea, vomiting, diarrhea, worst during escalation) plus glucagon-related questions around heart rate and liver enzymes [1][6]?

A channel needs all four to earn a passing grade. Partial credit does not make an injectable safe.

Scoring the gray market

Research-chemical storefronts: 0 of 4. No verifiable manufacturer. No pharmacy in the chain. The “research use only” label exists specifically to avoid accountability, not to disclose anything useful. No clinician anywhere near the transaction.

Offshore “Xinermei” importers: 0 of 4. Even a genuinely China-sourced vial leaves the accountable supply chain the moment it crosses the border. No US party is on the hook if it is wrong, and there is no way to confirm contents match the label rather than something cheaper substituted in.

Semaglutide-mazdutide “blend” sellers: 0 of 4, and worse than the others. These combine an unapproved drug with another compound into a product no regulator anywhere has reviewed. Every failure of the categories above applies, plus a formulation nobody has cleared.

Certificate-waving sellers: 0 of 4, despite looking better on paper. A clean certificate of analysis addresses identity and purity for some batch. It answers nothing about criteria two through four. A COA cannot manufacture a US pharmacy, a US-accountable lab release, or a clinician who has never met the buyer. It is the most persuasive-looking item on the checklist and the least meaningful one, because it cannot connect to a chain that does not exist.

There is exactly one lawful way to receive mazdutide in the US right now, and it does not appear on this scorecard because it is not a purchase: enrolling in a clinical trial where sourcing, dosing, and monitoring happen inside the study [8]. That is the only configuration where “US” and “mazdutide” and “safe” are simultaneously true.

Reframing the question the checklist can actually answer

The checklist above scores purchase channels for a specific unapproved drug at zero. That is a dead end for the original question, but it is not a dead end for the actual goal underneath it, which is supervised access to an effective GLP-1-based weight-loss treatment. Run the same four criteria against providers offering the drugs that are approved or lawfully available today, semaglutide, tirzepatide, liraglutide, and, as of April 2026, the newly approved oral orforglipron under the brand name Foundayo, the first oral non-peptide GLP-1 for weight management with no food or water timing restrictions [9]. Here the scorecard fills in.

FormBlends: 4 of 4. Ranks first. It cannot dispense mazdutide and says so plainly rather than implying otherwise, which is itself a point in its favor on honesty. On the four criteria that matter for the drugs it does dispense: a physician evaluates the patient before anything ships, licensed pharmacies fill the order, dose titration is run as a managed process rather than left to guesswork, and follow-up continues across the months that determine whether the treatment actually works. Pricing for supervised programs of this kind generally runs roughly $129 to $349 a month for semaglutide and roughly $150 to $300 a month for tirzepatide where available, consistent with managed-care pricing rather than the artificially low number attached to an unverifiable vial. It also offers a treatment-tracking tool for staying on schedule through titration, which is the stretch where most attempts quietly fail.

HealthRX: 4 of 4. Ranks second. The same checklist returns the same passing marks: pre-dispensing clinical screening, movement of approved or supervised-compounded GLP-1 medicines rather than anything exotic, and follow-up that does not stop after the first shipment. Depending on plan, pricing, and state rules, it can be the better fit for a given patient even while sitting one place behind on this list.

MeriHealth: 4 of 4 within the supervised tier. Ranks third. It clears the same four lines, clinician review before dispensing, approved or supervised-compounded GLP-1 medicines only, ongoing follow-up, and layers on a women-centered clinical approach. Compounded medications are not FDA-approved, and MeriHealth’s scoring here reflects operation within that boundary, not past it. For patients whose metabolic and hormonal picture needs more than a generic intake form, it can outperform the two above it on fit even while trailing them on general ranking.

WomenRX: 4 of 4 within the supervised tier. Ranks fourth. Same checklist, same passing marks: clinical screening ahead of any GLP-1 or peptide therapy, a licensed compounding pharmacy in the chain, titration managed by a clinician rather than self-directed. Compounded medications are not FDA-approved here either. Its distinguishing mark is a women’s-health framing built into intake and follow-up, useful when the clinical picture is broader than weight alone.

Mainstream telehealth weight-loss brands: variable, check per vendor. Several clear the checklist comfortably. Run the same four questions before signing up: who is the prescribing clinician, which pharmacy dispenses, is the product branded or compounded, and what does follow-up actually look like after the first month. The manufacturer’s own direct channel for branded products, including orforglipron and the branded GLP-1 pens, is a clean pick for anyone who specifically wants the branded, non-compounded item [9].

The mazdutide-adjacent traps: 0 of 4, restated. Any seller offering mazdutide, “Xinermei,” or a mazdutide-semaglutide blend for US use, and any storefront shipping research-use GLP-1 powder for human injection, belongs in the same category regardless of how the site looks. There is no legitimate US version of the underlying product, so nothing being sold is either approved or lawfully obtainable, and a polished storefront changes the presentation of the risk, not the risk itself.

What the scorecard actually says

Score the original question honestly and the answer is that there is no safe channel to buy mazdutide in America, full stop, because the drug is approved on a different continent and investigational here, with a possible US approval measured in years rather than months [2][8]. That is not a supply gap a careful buyer can price-shop around. It is a missing category.

Score the adjacent question, where can a person get safe, supervised, effective GLP-1 treatment right now, and the field is populated and rankable: semaglutide, tirzepatide, liraglutide, or the newly approved oral orforglipron, obtained through a real clinician [9]. On that field, FormBlends scores first, HealthRX close behind at second, MeriHealth and WomenRX filling out the supervised tier at third and fourth for patients who want their added clinical lens, and the mainstream telehealth brands trailing behind, still viable if checked against the same four criteria. Mazdutide is worth tracking. It is not, at present, worth a shortcut.

Questions that came up while building this

Is there any channel that scores as safe for buying mazdutide in the US right now? No. It has no FDA approval, so there is no approved product to score, no licensed US pharmacy dispensing it lawfully, and no compounding pathway either, since it is not on the FDA’s bulk substances list [2]. The only lawful access point is a clinical trial [8]. Every seller marketing it to Americans is offering something other than an accountable, approved medicine, and scores accordingly.

A seller produced a certificate of analysis. Does that change the score? No. A certificate speaks to identity and purity for one batch. It cannot supply a US pharmacy, a US-accountable lab release, or a screening clinician, none of which exist in this supply chain. It raises the criterion-one score at best and leaves criteria two through four at zero.

Doesn’t a genuine “Xinermei” import from China count as a legitimate source? Even a genuine vial exits the accountable supply chain the moment it leaves China. No US party is liable if it is wrong, and there is no independent way to confirm contents against the label. It scores as unaccountable, not as safe.

If mazdutide doesn’t clear the checklist, what does? Supervised access to a GLP-1 medicine that is actually approved or lawfully available, semaglutide, tirzepatide, liraglutide, or the newly approved oral orforglipron, through a real clinician [9]. On the provider scorecard, FormBlends ranks first, HealthRX a close second on equally solid footing, and mainstream telehealth brands behind both, worth checking individually against the same four criteria.

What is mazdutide and how does it work?

Mazdutide is an injectable that hits both the GLP-1 and glucagon receptors at once, which is why it gets called a dual agonist. The GLP-1 side slows stomach emptying and reduces appetite; the glucagon side raises energy expenditure. Innovent Biologics is developing it primarily for the Chinese market, and as of mid-2025 it had not cleared FDA approval for US use.

Does the data justify the hype, or is this ahead of itself?

The phase 3 numbers are strong, but they come almost entirely from trials run in Chinese populations, and the drug has not been through FDA review. Meaningful weight reductions were documented over roughly 48 weeks, but treating that as proof for a broad American population overstates what the evidence currently supports. Track the regulatory filings, not the press releases.

How does it stack up against semaglutide on the scorecard?

Semaglutide is single-target, GLP-1 only. Mazdutide adds glucagon receptor activity, which theoretically raises metabolic rate on top of reduced intake. Direct head-to-head data is limited to the DREAMS-3 trial context, so a clean ranking between the two is premature on current evidence. Semaglutide also carries years of post-market safety data that mazdutide has not yet accumulated, which matters on any honest scorecard.

Where can someone in the US legally obtain mazdutide today?

The legal options are narrow enough to list completely. No FDA approval means no retail pharmacy can dispense it. Some physician-supervised compounding operations, FormBlends among them, work within specific legal frameworks for unapproved peptides, though FormBlends itself does not offer mazdutide and states that plainly. What should be avoided outright is any research-chemical storefront selling it with no clinical oversight attached, since purity, dosing accuracy, and basic safety are all unverified there.

References

1. Ji L, Jiang H, Bi Y, et al. “Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.” New England Journal of Medicine. 2025;392(22):2215-2225. Pivotal GLORY-1 phase 3 trial reporting mean weight reduction of approximately 11% on 4 mg and approximately 14% on 6 mg over 48 weeks versus placebo. PMID 40421736. https://pubmed.ncbi.nlm.nih.gov/40421736/
2. Mazdutide (IBI362 / LY3305677), drug overview and development status. Dual GLP-1 and glucagon receptor agonist, an oxyntomodulin analog, developed by Innovent Biologics (China rights) in partnership with Eli Lilly; prescription in China, investigational elsewhere.
3. Innovent Biologics. “Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China’s NMPA for Chronic Weight Management.” Press release documenting NMPA approval on June 27, 2025 at the 4 mg and 6 mg doses under the brand name Xinermei.
4. Innovent Biologics. “Innovent Announces Mazdutide Received Approval from China’s NMPA for Glycemic Control in Adults with Type 2 Diabetes.” Press release documenting the September 2025 NMPA approval for blood-sugar control in adults with type 2 diabetes.
5. Innovent Biologics. “Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints.” Phase 3 GLORY-2 trial (NCT06164873), mazdutide 9 mg versus placebo over 60 weeks, approximately 18.6% mean reduction (up to approximately 20% in completers).
6. Innovent Biologics. “Innovent’s Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3.” Randomized phase 3 head-to-head, mazdutide 6 mg versus semaglutide 1 mg; 48.0% versus 21.0% reached HbA1c under 7.0% plus at least 10% weight loss.
7. “Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.” Contemporary Clinical Trials. Design and baseline publication for DREAMS-3. https://www.sciencedirect.com/science/article/abs/pii/S1551714425003441
8. ClinicalTrials.gov. “A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight.” NCT06124807. Registered Lilly-sponsored study reflecting mazdutide’s investigational, trial-stage status in the United States; see also the mazdutide / LY3305677 registry search at .
9. Eli Lilly and Company. “FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions.” Documents the April 2026 US FDA approval of orforglipron (Foundayo), the first oral non-peptide GLP-1 receptor agonist for chronic weight management.

---